These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 23791221)

  • 1. Systemic absorption and pharmacokinetics of single-dose early intravesical mitomycin C after transurethral resection of non-muscle-invasive bladder cancer.
    Maffezzini M; Campodonico F; Manuputty EE; Puntoni M; Martelli A; Marini V; Tamagno S; Mattioli F
    Urology; 2013 Aug; 82(2):400-4. PubMed ID: 23791221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial.
    Di Stasi SM; Valenti M; Verri C; Liberati E; Giurioli A; Leprini G; Masedu F; Ricci AR; Micali F; Vespasiani G
    Lancet Oncol; 2011 Sep; 12(9):871-9. PubMed ID: 21831711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of intravesical mitomycin C in superficial bladder cancer patients.
    Dalton JT; Wientjes MG; Badalament RA; Drago JR; Au JL
    Cancer Res; 1991 Oct; 51(19):5144-52. PubMed ID: 1913640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravesical thermo-chemotherapy based on conductive heat: a first pharmacokinetic study with mitomycin C in superficial transitional cell carcinoma patients.
    Milla P; Fiorito C; Soria F; Arpicco S; Cattel L; Gontero P
    Cancer Chemother Pharmacol; 2014 Mar; 73(3):503-9. PubMed ID: 24442034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of local hyperthermia of the bladder on mitomycin C pharmacokinetics during intravesical chemotherapy for the treatment of superficial transitional cell carcinoma.
    Paroni R; Salonia A; Lev A; Da Pozzo LF; Cighetti G; Montorsi F; Rigatti P; Colombo R
    Br J Clin Pharmacol; 2001 Sep; 52(3):273-8. PubMed ID: 11560559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study.
    Di Stasi SM; Giannantoni A; Stephen RL; Capelli G; Navarra P; Massoud R; Vespasiani G
    J Urol; 2003 Sep; 170(3):777-82. PubMed ID: 12913696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immediate administration of intravesical mitomycin C after tumour resection for superficial bladder cancer.
    Mostafid AH; Rajkumar RG; Stewart AB; Singh R
    BJU Int; 2006 Mar; 97(3):509-12. PubMed ID: 16469017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Value of an Immediate Intravesical Instillation of Mitomycin C in Patients with Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Randomised Study in 2243 patients.
    Bosschieter J; Nieuwenhuijzen JA; van Ginkel T; Vis AN; Witte B; Newling D; Beckers GMA; van Moorselaar RJA
    Eur Urol; 2018 Feb; 73(2):226-232. PubMed ID: 28705539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contemporary cost analysis of single instillation of mitomycin after transurethral resection of bladder tumor in a universal health care system.
    Feifer A; Xie X; Brophy JM; Segal R; Kassouf W
    Urology; 2010 Sep; 76(3):652-6. PubMed ID: 20394970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single instillation of mitomycin C reduces 1st year recurrence following transurethral resection of non-muscle invasive bladder cancer.
    Ather MH; Aziz S; Sulaiman MN
    J Ayub Med Coll Abbottabad; 2007; 19(4):18-20. PubMed ID: 18693589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increasing medical staff safety by using a closed system for intravesical instillation of mitomycin C.
    Haifler M; Lang E; Sabler I; Gutman Y; Lindner A; Zisman A
    Urology; 2010 Sep; 76(3):649-51. PubMed ID: 20493518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial.
    Divrik RT; Yildirim U; Zorlu F; Ozen H
    J Urol; 2006 May; 175(5):1641-4. PubMed ID: 16600720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bladder perforation: a potential risk of early endovesical chemotherapy with mitomycin C.
    Racioppi M; Porreca A; Foschi N; Delicato G; Destito A; D'Addessi A
    Urol Int; 2005; 75(4):373-5. PubMed ID: 16327311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early and large-dose intravesical instillation of epirubicin to prevent superficial bladder carcinoma recurrence after transurethral resection.
    Mitsumori K; Tsuchiya N; Habuchi T; Li Z; Akao T; Ohyama C; Sato K; Kato T
    BJU Int; 2004 Aug; 94(3):317-21. PubMed ID: 15291859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced Quality and Effectiveness of Transurethral Resection of Bladder Tumour in Non-muscle-invasive Bladder Cancer: A Multicentre Real-world Experience from Scotland's Quality Performance Indicators Programme.
    Mariappan P; Johnston A; Padovani L; Clark E; Trail M; Hamid S; Hollins G; Simpson H; Thomas BG; Hasan R; Bhatt J; Ahmad I; Nandwani GM; Mitchell IDC; Hendry D;
    Eur Urol; 2020 Oct; 78(4):520-530. PubMed ID: 32690321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Destruction of the bladder by single dose Mitomycin C for low-stage transitional cell carcinoma (TCC)--avoidance, recognition, management and consent.
    Elmamoun MH; Christmas TJ; Woodhouse CR
    BJU Int; 2014 May; 113(5b):E34-8. PubMed ID: 24053461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic absorption and pharmacokinetics of single-dose intravesical gemcitabine after transurethral resection of the bladder in non-muscle-invasive bladder cancer.
    Maffezzini M; Campodonico F; Puntoni M; Martelli A; Mattioli F
    Urology; 2009 Nov; 74(5):1078-83. PubMed ID: 19773039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single ablative intravesical electromotive mitomycin C administration for small non-muscle-invasive bladder cancer: a prospective study.
    Decaestecker K; Lumen N; Van Camp C; Oosterlinck W
    Acta Clin Belg; 2018 Oct; 73(5):324-327. PubMed ID: 29451102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cationic core-shell nanoparticles for intravesical chemotherapy in tumor-induced rat model: safety and efficacy.
    Erdogar N; İskit AB; Eroglu H; Sargon MF; Mungan NA; Bilensoy E
    Int J Pharm; 2014 Aug; 471(1-2):1-9. PubMed ID: 24836669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of timing of an immediate instillation of mitomycin C after transurethral resection in 941 patients with non-muscle-invasive bladder cancer.
    Bosschieter J; van Moorselaar RJA; Vis AN; van Ginkel T; Lissenberg-Witte BI; Beckers GMA; Nieuwenhuijzen JA
    BJU Int; 2018 Oct; 122(4):571-575. PubMed ID: 29319922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.